← Patent-cliff monitor Loss of exclusivity February 2041 latest FDA-listed patent expiry
Company JAZZ PHARMACEUTICALS IRELAND LTD
Drug detail Brand name XYWAV Active ingredient CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE Strength 0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML Dosage form SOLUTION Route ORAL Modality Small molecule FDA approval July 2020 Marketing status RX
Listed patents Patent Expires Type 12138233 February 2041 use U-4044 12582622 February 2041 use U-4044 11426373 September 2037 use U-3432 9486426*PED September 2033 — 9050302*PED September 2033 — 11253494*PED September 2033 — 10213400*PED September 2033 — 10864181*PED September 2033 — 8772306*PED September 2033 — 8772306 March 2033 use U-1532 11986446 March 2033 use U-3324 9050302 March 2033 use U-1532 10213400 March 2033 use U-2499 9486426 March 2033 use U-1532 10864181 March 2033 use U-3017 11253494 March 2033 use U-3324 11554102 January 2033 product 8591922 January 2033 product 10195168 January 2033 product 8901173 January 2033 product 9132107 January 2033 product 10675258 January 2033 use U-2938
Regulatory exclusivity Code Expires ODE-369 August 2028 PED January 2028 ODE-361 July 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.